AU2019292557A1 - Pharmaceutical compositions and methods for the treatment of thrombosis and delivery by medical devices - Google Patents

Pharmaceutical compositions and methods for the treatment of thrombosis and delivery by medical devices Download PDF

Info

Publication number
AU2019292557A1
AU2019292557A1 AU2019292557A AU2019292557A AU2019292557A1 AU 2019292557 A1 AU2019292557 A1 AU 2019292557A1 AU 2019292557 A AU2019292557 A AU 2019292557A AU 2019292557 A AU2019292557 A AU 2019292557A AU 2019292557 A1 AU2019292557 A1 AU 2019292557A1
Authority
AU
Australia
Prior art keywords
thrombus
pharmaceutical composition
enzymes
balloon
proteolytic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2019292557A
Other languages
English (en)
Inventor
Michael K. HANDLEY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marizyme Inc
Original Assignee
Marizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marizyme Inc filed Critical Marizyme Inc
Publication of AU2019292557A1 publication Critical patent/AU2019292557A1/en
Assigned to MARIZYME, INC. reassignment MARIZYME, INC. Amend patent request/document other than specification (104) Assignors: MARIZYME BIOTECH
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4806—Hydrolases (3) acting on peptide bonds (3.4) from animals other than mammals, e.g. snakes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21001—Chymotrypsin (3.4.21.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21004—Trypsin (3.4.21.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12027—Type of occlusion
    • A61B17/12036—Type of occlusion partial occlusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12027—Type of occlusion
    • A61B17/1204—Type of occlusion temporary occlusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/12136—Balloons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M2025/1043—Balloon catheters with special features or adapted for special applications
    • A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M2025/1043—Balloon catheters with special features or adapted for special applications
    • A61M2025/1052—Balloon catheters with special features or adapted for special applications for temporarily occluding a vessel for isolating a sector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Surgical Instruments (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
AU2019292557A 2018-06-28 2019-06-28 Pharmaceutical compositions and methods for the treatment of thrombosis and delivery by medical devices Pending AU2019292557A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862691319P 2018-06-28 2018-06-28
US62/691,319 2018-06-28
PCT/US2019/039878 WO2020006444A1 (en) 2018-06-28 2019-06-28 Pharmaceutical compositions and methods for the treatment of thrombosis and delivery by medical devices

Publications (1)

Publication Number Publication Date
AU2019292557A1 true AU2019292557A1 (en) 2021-04-01

Family

ID=68985200

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019292557A Pending AU2019292557A1 (en) 2018-06-28 2019-06-28 Pharmaceutical compositions and methods for the treatment of thrombosis and delivery by medical devices

Country Status (9)

Country Link
EP (1) EP3813687A4 (de)
JP (1) JP2022525713A (de)
CN (1) CN112638289A (de)
AU (1) AU2019292557A1 (de)
BR (1) BR112021004809A2 (de)
CA (1) CA3110779A1 (de)
CR (1) CR20210059A (de)
EA (1) EA202190494A1 (de)
WO (1) WO2020006444A1 (de)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6130527A (ja) * 1984-07-20 1986-02-12 Kao Corp 血栓溶解剤
AU7278094A (en) * 1994-06-07 1996-01-04 M D Serv Europe S.A. Intravasal thrombolysis
US6022309A (en) * 1996-04-24 2000-02-08 The Regents Of The University Of California Opto-acoustic thrombolysis
FR2797768B1 (fr) * 1999-09-01 2003-06-13 Ifremer Utilisation d'un polysaccharide sulfate de bas poids moleculaire pour l'obtention d'un medicament actif contre la thrombose vasculaire
US20040241249A1 (en) * 2001-06-18 2004-12-02 Tina Sampalis Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases arthritis, skin cancer diabetes, premenstrual syndrome and transdermal transport
CN1327893C (zh) * 2001-10-01 2007-07-25 布雷德利 胶原酶在促进导线在完全动脉闭塞内通过中的应用
CN1210036C (zh) * 2002-06-18 2005-07-13 蚌埠丰原医药科技发展有限公司 赖氨匹林的新用途
SE0303588D0 (sv) * 2003-12-30 2003-12-30 Bioactive Polymers Ab C O Lund Surface protection of exposed biological tissues
JP4677557B2 (ja) * 2005-05-11 2011-04-27 国立大学法人東北大学 超音波プローブ及びそれを用いたカテーテル並びにその製造方法
EP1726301A1 (de) * 2005-05-24 2006-11-29 Flamel Technologies Pharmazeutische Zusammensetzung zur Behandlung COX-2 vermittelter Krankheiten
DE102005042338B4 (de) * 2005-09-06 2007-07-05 Siemens Ag Kathetereinrichtung
AR059012A1 (es) * 2006-01-13 2008-03-05 Aker Biomarine Asa Extractos derivados del krill
US20130287757A1 (en) * 2011-01-13 2013-10-31 Medestea Internazionale S.P.A. Composition for the regeneration of atrophic tissues
EP3071125B1 (de) * 2013-11-18 2021-08-04 Koninklijke Philips N.V. Vorrichtungen zur thrombenstreuung
DE202015002060U1 (de) * 2015-03-17 2015-11-25 Gerhard-Friedrich Horak Infusions- und Aspirations- Catheter (IAC) (Katheter zur Entfernung von Thromben und Applikation von Medikamenten)
US10973681B2 (en) * 2016-08-12 2021-04-13 Clearside Biomedical, Inc. Devices and methods for adjusting the insertion depth of a needle for medicament delivery
EP3554611A1 (de) * 2016-12-13 2019-10-23 Boston Scientific Scimed Inc. Thrombolysekathetersystem

Also Published As

Publication number Publication date
EP3813687A1 (de) 2021-05-05
WO2020006444A1 (en) 2020-01-02
BR112021004809A2 (pt) 2021-06-22
CN112638289A (zh) 2021-04-09
EP3813687A4 (de) 2022-03-23
CA3110779A1 (en) 2020-01-02
JP2022525713A (ja) 2022-05-19
EA202190494A1 (ru) 2021-12-09
CR20210059A (es) 2021-12-23

Similar Documents

Publication Publication Date Title
JPH0640924A (ja) アテローム性動脈硬化に伴う血栓の再発を防止するための溶液
Stock et al. Massive pulmonary embolism: treatment with thrombus fragmentation and local fibrinolysis with recombinant human-tissue plasminogen activator
Gauberti et al. Thrombolytic strategies for ischemic stroke in the thrombectomy era
Liu et al. Catheter-directed thrombolysis for acute iliofemoral deep venous thrombosis
ES2396964T3 (es) Uso de colagenasa para facilitar el cruce con alambre de guia de oclusiones arteriales crónicas
Reimer et al. Use of rheolytic thrombectomy in the treatment of feline distal aortic thromboembolism
AU2003279258A1 (en) Method for treatment of indwelling catheter occlusion using fibrinolytic metalloproteinases
US20100330083A1 (en) Plasminogen activator variant formulations
Chaise et al. Selective intra-arterial streptokinase therapy in the immediate postoperative period
US20200405332A1 (en) Pharmaceutical compositions and methods for the treatment of thrombosis and delivery by medical devices
Marques et al. Post-catheterisation arterial thrombosis in children–pathophysiology, prevention, and treatment
AU2019292557A1 (en) Pharmaceutical compositions and methods for the treatment of thrombosis and delivery by medical devices
Bookstein et al. Pulse-Spray Pharmacomechanical Thrombolysis-Updated Clinical and Laboratory Observations
Krakovsky et al. THR-18, a 18-mer peptide derived from PAI-1, is neuroprotective and improves thrombolysis by tPA in rat stroke models
Wongwanit et al. Treatment of iatrogenic pseudoaneurysm of brachial artery with percutaneous ultrasonographically guided thrombin injection (PUGTI): a case report and a literature review
Lei et al. Intra-arterial infusion of tirofiban and urokinase for thromboembolic complications during coil embolization of ruptured intracranial aneurysms
Riggs et al. Thrombolysis in the treatment of lower extremity occlusive disease
Towne et al. Application of thrombolytic therapy in vascular occlusive disease: a surgical view
LAIRD The management of acute limb ischemia: techniques for dealing with thrombus
Tomaru et al. Local treatment with an antithrombotic drug reduces thrombus size in coronary and peripheral thrombosed arteries
Mitchell et al. Plasmin (Human) administration in acute middle cerebral artery ischemic stroke: phase 1/2a, open-label, dose-escalation, safety study
Gupta et al. Bilateral Catheter-Directed Thrombolysis for an Acute Bilateral Pulmonary Embolism Patient with Severe Right Ventricular Strain: from Intensive Care Unit to Home on Postoperative Day 1.
FEUGIER et al. The Place of Thrombolysis in the Treatment of Peripheral Arterial Thrombosis
Verstraete 9 Thrombolytic therapy of non-cardiac disorders
Mularczyk et al. Fibrinolytic intra-arterial therapy in treatment of arterial occlusion in femoropopliteal segment

Legal Events

Date Code Title Description
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO ENTER THE NATIONAL PHASE HAS BEEN EXTENDED TO 28 MAR 2021

HB Alteration of name in register

Owner name: MARIZYME, INC.

Free format text: FORMER NAME(S): MARIZYME BIOTECH